Yangyang Yu

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Yongxiang Xia, Weiwei Tang, Xiaofeng Qian et al. · Journal for ImmunoTherapy of Cancer · 2022 · 211 citations · Full text

Medicine, Oncology, Pharmacology +17

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Hui Li, Yongchang Zhang, Yanjun Xu et al. · Cell Death and Disease · 2022 · 31 citations · Full text

Medicine, Immunology, Oncology +17

CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer

Yan Zhao, Yangyang Yu, Xiangmin Li et al. · Journal of Experimental & Clinical Cancer Research · 2024 · 20 citations · Full text

Medicine, Cancer Biology, Oncology +17

<i>PAPPA2</i> mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and <scp>non‐small</scp> cell lung cancer

Yiting Dong, Lele Zhao, Jianchun Duan et al. · Cell Proliferation · 2022 · 16 citations · Full text

Life Sciences, Immunology, Oncology +17